| Assessment Status | Rapid Review Complete |
| HTA ID | 23076 |
| Drug | Netarsudil-latanoprost |
| Brand | Roclanda® |
| Indication | Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intraocular pressure reduction. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2023 |
| Rapid review completed | 22/02/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that netarsudil-latanoprost be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. May 2024
